DocGo Inc. reiterated earnings guidance for the fiscal year 2022. The company is reiterating its prior revenue guidance for fiscal year 2022 of approximately $400 million to $420 million. This represents growth of 25% to 32% over 2021 revenues.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.04 USD | -1.30% | -3.80% | -45.62% |
May. 09 | Cantor Fitzgerald Adjusts DocGo Price Target to $5 From $11, Maintains Overweight Rating | MT |
May. 09 | Deutsche Bank Adjusts DocGo Price Target to $5 From $8.20, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.62% | 313M | |
+1.13% | 3.09B | |
0.00% | 1.97B | |
+19.18% | 1.79B | |
+66.09% | 692M | |
-13.53% | 414M | |
-21.08% | 170M | |
-15.15% | 135M | |
+3.85% | 67.94M |
- Stock Market
- Equities
- DCGO Stock
- News DocGo Inc.
- DocGo Inc. Reiterates Earnings Guidance for the Fiscal Year 2022